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Background: Osteoporosis (OP) and osteoarthritis (OA) are prevalent skeletal disorders among postmenopausal
women. Coexistence is common especially that of postmenopausal osteoporosis (PMO) and lumbar OA. An hypothesis
has been raised that OP and OA might share the same pathogenic mechanism, and pulsed electromagnetic fields
(PEMFs) were reported to have anti-osteoporosis and anti-osteoarthritis properties, but this suggestion was based
primarily on biomarker data. Therefore, whether these two effects could take place simultaneously has not yet been
investigated. This randomized controlled trial (RCT) is designed to explore the effect of PEMFs for PMO and
concomitant lumbar OA.
Methods/Design: The study will include PMO patients (postmenopausal women; aged between 50 and 70 years; have
been postmenopausal for at least 5 years and diagnosed with OP using proximal femur T-score) with concomitant
lumbar OA (patients with confounding disorders like diabetes, hypertension, hyperlipidemia, and previous fracture
history, etcetera, will be excluded) will be randomly assigned to two arms: PEMFs group and sham PEMFs group. There
will be 25 participants in each arm (50 in total) and the outcome assessment, including the primary endpoint (proximal
femur bone mineral density), will be performed at 5 weeks, 3 months and 6 months after enrollment.
Discussion: PMO and lumbar OA are prominent public health problem, especially for postmenopausal women. We
hope this RCT will provide scientific evidence to primary care of the postmenopausal women regarding the use of
these nonpharmaceutical, noninvasive modalities, PEMFs, in managing PMO and lumbar OA.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-14005156 (28 August 2014).
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Osteoporosis (OP) is characterized by low bone mass
and microarchitectural deterioration of bony tissue, with
a consequent increase in bone fragility and risk of frac-
tures [1]. This systemic skeletal disease is clinically diag-
nosed by evaluating bone mineral density (BMD) using
dual-energy X-ray absorptiometry (DXA) according to
the WHO criteria [2]. Another prevalent skeletal dis-
order among postmenopausal women is osteoarthritis
(OA). It involves a series of pathological changes not
only in articular cartilage but also the underlying bone
[3], which will probably increase average BMD and
interfere with the capability of DXA in detecting OP.
In clinical practice, proximal femur and lumbar spine
are the two most common sites measured for BMD
assessment. For the former, the most vulnerable region
to hip OA is the femur head, which is not included in
the measurement, so BMD values of proximal femur
are believed to be accurate to some extent. The spine is
also susceptible to OA, and spinal OA affects almost
80 % of those aged 40 or above [4]. More specifically,
since the thoracic segments are “splinting” by the cost-
overtebral joints, and the cervical spine has relatively
low need for weight-bearing, the lumbar segments
are regarded as the most susceptible region of the spine
to OA [5]. So the coexistence of OP and lumbar OA
is common and the diagnosis of OP was suggested
to be made based on values of hip BMD rather than
that of lumbar spine, unless lumbar OA was not
present [6, 7].
On the other hand, the relationship between OP and
OA is complicated and controversial [8, 9]. One hypoth-
esis is that they might share the same pathogenic mech-
anism since it was found that excessive bone resorption,
a hallmark of OP, also took place in the early stage in
the development of OA. This finding and hypothesis are
inspiring, since they indicate there might be treatments
that could be used to treat OP and OA at the same time
[9–12].
Pulsed electromagnetic fields (PEMFs) might be clas-
sified as these treatments, because both anti-osteoporosis
and anti-osteoarthritis effects have been reported respect-
ively, but primarily with biomarker data [13–24]. No
clinical research has ever been conducted to explore the
anti-osteoporosis and anti-osteoarthritis effects of PEMFs
simultaneously, especially using clinical data. In the clin-
ical setting, the coexistence of postmenopausal osteopor-
osis (PMO) and lumbar OA is common, and if treatments
could be applied to cope with these two problems at the
same time, such a treatment would be significant. The pri-
mary goal of this randomized controlled trial (RCT) is to
explore these two effects by treating PMO (diagnosed by
evaluating BMD of proximal femur) with concomitant
lumbar OA in southwest China.Methods/Design
Study design
The research will be a prospective parallel, single-blinded
(assessor and participants) RCT with a follow-up period of
6 months. After baseline assessment, participants will be
randomized into two arms: PEMFs group and sham
PEMFs group (Fig. 1). This randomization process will be
automatically performed using software and sequential
sealed envelopes by an independent statistician once a
patient will be considered eligible. The sealed envelopes
will be opened for each participants, and the statistician
will make a record of the allocation.
Participants will receive PEMFs or sham PEMFs treat-
ment for the first 5 weeks after enrollment. Outcome as-
sessment will be performed at the following time
points: 5 weeks, 3 months and 6 months after enroll-
ment (Additional file 1).
This RCT is planned to be single blinded (assessor and
patient). Furthermore, statisticians carrying out the stat-
istical analyses will also be blind to group allocation
until the analyses are completed.
This protocol conforms to CONSORT guidelines for
nonpharmacological studies [25], in accordance with the
ethical standards in the 1964 Declaration of Helsinki
and was approved by the clinical research and biomed-
ical ethics committee of the West China Hospital,
Sichuan University (ethics reference: 2014 (114)). Writ-
ten and signed informed consent will be obtained from
all participants prior to inclusion in the study. This trial
has been registered in the Chinese Clinical Trial Registry
(No. ChiCTR-TRC-14005156).
Participants
To be eligible, participants must meet the following cri-
teria: (1) is a postmenopausal woman; (2) aged between
50 and 70 years; (3) has been postmenopausal for at least
5 years and diagnosed with OP (proximal femur T-score
equal to or lower than -2.5) [2, 7]. Women with sus-
pected confounding disorders (for example, diabetes
mellitus, hypertension, hyperlipidemia, obesity, second-
ary and idiopathic osteoporosis, fracture history, sys-
temic inflammatory disorders, visual impairment, severe
vestibular lesions, cerebellar lesions, peripheral nerve or
muscle disease, mental retardation, mental illness, cogni-
tive impairment, obstetrical and gynecological diseases,
blood disease, stroke or venous thromboembolic disease,
thyroid, parathyroid, adrenal, hepatic and renal disease,
malignancy, etcetera), who had received anti-osteoporosis
treatment within 6 months before inclusion, and those not
suitable to be included for any other reason not mentioned
above will all be excluded.
Participants fulfilling the above criteria will receive fur-
ther lateral lumbar spine radiography, and those with
concomitant lumbar OA will finally be included. The
Fig. 1 Trial flow. PEMFs, pulsed electromagnetic fields
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two or more criteria fulfilled according to Kellgren and
Lawrence [26]. Two technicians will independently read
the radiographs and in case of discrepancy, a third tech-
nician will be consulted to reach consensus. Further
exclusion criteria are as follows: (1) secondary OA;
(2) congenital spinal diseases; (3) scoliosis; (4) spondylo-
listhesis - spondylolysis; (5) history of spinal surgery; (6)
inflammatory arthropathy; or (7) individuals who have
had facet joint injection or any physical therapy (for ex-
ample, chiropractic, osteopathy or physiotherapy treat-
ment) for back pain in the previous 6 months.
Interventions
All included participants will receive conventional usual
care (600 mg/day calcium and alfacalcidol vitamin D
supplement 0.25 μg/bid) throughout the study period.
Participants allocated to the PEMFs group will receive
additional PEMFs treatment (40 min/treatment, 1 treat-
ment session/day, 6 treatment sessions/week, for a total
of 30 times as one course of treatment) for the first
5 weeks after enrollment, while those assigned to the
sham PEMFs group will receive sham PEMFs treatment
with the same device but no stimulus generated, indis-
tinguishable from the real ones.
The PEMFs treatment will be applied using XT-2000B
therapeutic stimulators (Tianjin xtmed, Tianjin, China)
to generate time-varying fields consisting of bursts ofasymmetric pulses. Each burst should last for 0.2 ms and
repeat at a frequency of 8 Hz. The fields will be deliv-
ered perpendicular to the lumbar spine and proximal
femur of the supine participant and the flux density within
a single burst will start with a peak value of 3.82 mT and
decrease to 0 mT in 0.2 ms.
All participants will be asked to refrain from seeking
any other physiotherapy or medications throughout the
study period, especially during the first 5 weeks after en-
rollment, when PEMFs are proposed to be delivered.
Whereas afterwards, during the follow-up phase when
all participants are scheduled to receive only usual care,
the use of analgesia and non-steroidal anti-inflammatory
drugs (NSAIDs) will be permitted for the sake of ethical
considerations. However, the use of this sort of medica-
tions should not exceed 3 days in each week and should
not occur within 48 h of a follow-up visit. Information
regarding the types of treatments and corresponding
consumptions will be collected at each visit, and com-
parability between groups will be tested using Mann-
Whitney’s U-test.
Sample size
Because we could not identify data or citations proving
references for the minimum clinically significant differ-
ence and corresponding standard deviation in proximal
femur bone mineral density (BMDF) between the two
arms, the “least detectable longitudinal change measured
Liu et al. Trials  (2015) 16:265 Page 4 of 7using dual-energy X-ray absorptiometry (DXA), that is,
0.023” was approximately used as the expected absolute
intergroup difference and standard deviation [20, 27].
With a type I error probability of 5 % and a 90 % prob-
ability of avoiding a type II error, we would require 20
participants in each group. Assuming a loss to follow-up
of 20 %, a total sample size of 50 participants (25 partici-
pants per group) is needed.
We did additional sample size calculation for pain in-
tensity, the most important secondary endpoint, mea-
sured using the Visual Analogue Scale (VAS) on a scale
of 0 to 100. With a standard deviation of 32.17 [28], type
I error of 5 %, 90 % power, and a 20 % drop-out rate, ap-
proximately 25 patients would be needed in each group
to show a minimum clinically significant difference, 30-
points between groups [29].
Assessment
The primary outcome will be the mean percentage
change in BMDF at 6-month follow-up. Proposed sec-
ondary outcomes were listed below: VAS; The mean per-
centage changes in bone mineral density of the lumbar
spine (BMDL); serum 25-hydroxy-vitamin D (25(OH) D)
concentrations; Oswestry Disability Index (ODI); manual
muscle test (MMT) score; Berg Balance Scale (BBS)
score; Timed Up and Go Test (TUG); hemorheological
determinants; serum C-terminal telopeptide of type I
collagen (sCTX I), serum bone alkalin phosphatase
(sBALP), N-MID osteocalcin (N-MID); range of motion
(ROM) of lumbar spine; overall functional ability using
short form 36 item general health questionnaire (SF-36,
Quality Metric, Inc., Lincoln, Rhode Island, USA); treat-
ment compliance; health care consumption costs; possible
adverse events (Additional file 1). Detailed information on
some of the outcome measurements are described below:
As for BMD measurements, participants will be scanned
in the standard manner by a technician using DXA (GE
Lunar iDXA with encore 12.0 software, GE Healthcare
Lunar, Madison, WI) following recommendations from
the manufacturer. For proximal femur, BMD of the total
hip will be recorded and analyzed, while for the lumbar
spine the average BMD (aBMD) of the four vertebrae (L1-
L4) will be extracted. All these data could be directly ob-
tained using corresponding software without further
calculations.
Manual muscle strength of the lumbar and the lower-
extremity will be estimated by employing the MMT
method with the traditional six-point ordinal Medical
Research Council scale (0 to 5). Half-point scores will be
used between all grades except that of 4 and 5, since it
requires manual resistance that cannot be graded reliably
[30]. All tests will be performed by a single examiner.
Furthermore, before testing, the examiner and partici-
pants will all be required to rest for at least 5 min.The BBS is a set that comprises 14 simple balance re-
lated tasks, ranging from standing up from a sitting pos-
ition, to standing on one foot [31]. Another examiner
will perform the tests for all the participants following
the standard procedure. The examiner and participants
will also be required to rest for at least 5 min before
testing.
A TUG test will be conducted by recording the total
time that a person takes to rise from a chair, walk 3 me-
ters, turn around, walk back to the chair, and sit down
[32]. It is intended to evaluate the functional mobility of
the participants.
Adverse events will be recorded throughout the study
period. Having once occurred, the intensity and possible
relationship with the treatment will be examined and de-
scribed in detail.
Baseline assessment will be carried out after eligibility
and informed consent has been confirmed (Fig. 1). Apart
from outcome measurements, information referring to
participant’s age (in years), menopause age (in years),
time since menopause (in years), body mass index (BMI;
in kg/m2), comorbidities, duration of low back pain
symptoms, medication use, information referring to
physical activity (evaluated by the International Physical
Activity Questionnaire (IPAQ) short version [33]), sun-
light exposure (frequency and duration of time spent
outside, sun-protective-factor use), employment status,
occupation and dietary intake will all be collected.
Follow-up
After the first 5 weeks after enrollment, all participants
are scheduled to receive only usual care and the research
will go into the follow-up phase with scheduled follow-
up visits taking place at 5 weeks, 3 months and 6 months
after enrollment (Additional file 1). The last two time
points are designed to explore possible delayed effects of
PEMFs.
Data analysis
Continuous measurements will be expressed as means
and standard deviations (SD) and categorical measure-
ments will be summarized using numbers and percent-
ages. For all variables, descriptive statistics will be
calculated.
Our primary analysis of the data will be performed
using the principle of intention-to-treat (ITT). All par-
ticipants with a baseline value and at least one measure-
ment after randomization will be included in the efficacy
analyses using the last observation carried forward
(LOCF) method. It will consider all participants, includ-
ing those who are not fully compliant and those with
missing outcome data.
In addition, we will conduct sensitivity analysis by con-
ducting a per-protocol (PP) analysis for the primary
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compliance is good, which is defined as attendance of all
the scheduled visits, and low contamination (no other
treatment during the first 5 weeks after enrollment).Descriptive analyses at baseline
Baseline comparability between groups will be tested
using Pearson’s chi-square test or Fisher’s exact test for
categorical data, and Mann-Whitney’s U-test for con-
tinuous data. All baseline measurements will be analyzed.Primary analysis
Treatment differences will be assessed on the percentage
change from baseline to the three follow-up visits. Our
primary analysis will be conducted regarding the effect
of PEMFs on BMDF at 6 months. Descriptive statistics
for this variable will be presented for each intervention
group at each appointment during the 6-month follow-
up. Comparisons will be carried out using a mixed linear
model [34] with treatment group as a fixed factor and
time as a random factor. Adjustments will be made for
covariates including participant’s age, menopause age,
time since menopause, BMI, and the corresponding
baseline value. This model is supposed to be able to ap-
propriately control for correlation among multiple ob-
servations. Sensitivity analysis will also be carried out by
independent t-tests comparing changes between groups
from baseline to the end of follow-up. When intragroup
comparison is needed, paired sample t-tests will be also
applied.Secondary analyses
The analyses for the secondary outcome measurements
will be carried out in the same way as those mentioned
above. A mixed linear model will be applied, with treat-
ment group as a fixed factor, and time as a random
factor, adjusting for similar confounding factors. In
addition, to explore relationships among variables, we
will calculate Spearman’s or Pearson’s correlation coeffi-
cients along with their P values.Health economics evaluation
To determine whether the PEMFs are cost-effective to
pay for additional health gain, we will compute mean
(and SD) per patient costs and incremental cost-utility
ratios using quality-adjusted life-years (QALYs) derived
from SF-36 scores with appropriate preference weight-
ings [35, 36].
For all the analyses mentioned above, a two-sided
value of P <0.05 will be considered statistically signifi-
cant. All statistical analyses will be carried out using 19.0
SPSS software (SPSS, Chicago, IL).Discussion
This paper describes the rationale and protocol for con-
ducting a preliminary RCT in southwest China that will
investigate the effectiveness of PEMFs in treating PMO
and concomitant lumbar OA.
The idea originated from daily clinical practice since
the coexistence of OP and OA is not rare, especially that
of PMO and lumbar OA, which is frequently found dur-
ing BMD examinations using DXA. Furthermore, it was
found that excessive bone resorption also took place in
the early stage in the development of OA, indicating OP
and OA might share the same pathogenic mechanism
and could be treated simultaneously [9–12]. As for treat-
ment method, PEMFs have been reported to have anti-
osteoporosis and anti-osteoarthritis properties, but
whether these two effects would take place at the same
time has not yet been evaluated. Since the two skeletal
disorders, PMO and lumbar OA, are prevalent among
postmenopausal women and have a considerable impact
on both individuals and the society [37, 38], it would be
of great significance to identify effective treatments that
could deal with the two clinical problems simultaneously.
This trial will be the first RCT to investigate the effect
and cost-utility of PEMFs for PMO and concomitant
lumbar OA. The combination of clinical efficacy and
cost-effectiveness evidence is essential for health care de-
cisions. To find improvements for both OP and lumbar
OA and to facilitate comparability with other research,
we will include valid outcome measurements, and to
minimize bias, we will use BMDF, not BMDL, for the
diagnosis of OP, eliminating the interference of lumbar
OA for measuring BMD. Furthermore, we will choose
BMD (specifically the mean percentage change in
BMDF), instead of the incidence of fractures, as our pri-
mary endpoint, because a change in BMD offers the ad-
vantages of high precision, the ability to study multiple
skeletal sites in the same patient, and a relatively rapid
response to treatment [39, 40]. However, patient rele-
vance of any positive result of this trial will require a
follow-up trial with patient-relevant endpoints like frac-
ture and health economics evaluations using QALYs and
SF-36 scores informed by fracture data, etcetera, to pro-
vide further evidence.
We acknowledge limitations in the trial. First, the sam-
ple size calculation is somewhat imprecise, and there are
many secondary outcomes, all at 0.05 significance in a
trial with 25 subjects in each arm after accounting for a
20 % withdrawal. The risk of type I error may be very
high. Second, the primary endpoint is BMDF, which is
not as patient-relevant as fractures, so relevance of any
positive result of this trial to patients needs further in-
vestigations in large well-designed trials. In spite of these
limitations, our research also has strengths. One is that
we refined our exclusion criteria to eliminate potential
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patients with confounding disorders and concomitant
disorders that are of possibility to interfere with the bal-
ance of bone metabolism, and patients with lesions that
may not be able to fulfill the study assessment. Further-
more, those who received treatments within 6 months
before inclusion will also be excluded. Another one is
the utilization of a patient-blinded design, with sham
PEMFs arm to reduce the risk of bias. It is of great sig-
nificance especially for the assessment of patient-
reported outcomes (for example, pain), since without a
proper patient-blinded design, identified differences
could be interpreted as the results of placebo effect,
which is found effective in the treatment of OA, espe-
cially for pain, stiffness and self-reported function [41].
There are other trials that have used sham PEMFs suc-
cessfully. For example, Shi et al. evaluated outcomes of
postoperative delayed union of long-bone fractures
treated with an early application of PEMF, as compared
with a sham-treated control group, where the coil was
applied for 8 h/day with a sham signal generator from
the same manufacturer [42]; Nelson et al. examined the
pain-relieving effect of PEMFs and the sham devices
they used were activated with a switch and had blinking
indicator lights, just as active devices [43]. These two tri-
als had used sham PEMFs successfully, and their find-
ings were convincing.
In summary, this trial will provide preliminary evi-
dence regarding the use of a nonpharmaceutical, nonin-
vasive modality for managing PMO and lumbar OA.
The success of this study will provide scientific evidence
to primary care of postmenopausal women with these
two common skeletal disorders.Trial status
The trial is currently in the process of patient recruitment.Additional file
Additional file 1: Schedule of visits and measures to be made.
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